Stockscreener 앱 받기
6.81
1.30%
-0.09
전일 마감가:
$6.90
열려 있는:
$6.89
하루 거래량:
28,171
Relative Volume:
0.16
시가총액:
$247.46M
수익:
$16.10M
순이익/손실:
$-42.57M
주가수익비율:
-4.8288
EPS:
-1.4103
순현금흐름:
$-38.53M
1주 성능:
-0.29%
1개월 성능:
+3.97%
6개월 성능:
+3.18%
1년 성능:
+27.77%
1일 변동 폭
$6.75
$6.93
1주일 범위
$6.71
$6.99
52주 변동 폭
$3.76
$8.95
프로파운드 메디컬 Stock (PROF) Company Profile
명칭
Profound Medical Corp
전화
647-476-1350
주소
2400 SKYMARK AVENUE, UNIT 6, MISSISSAUGA, ON
Compare PROF vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PROF
Profound Medical Corp
|
6.81 | 250.73M | 16.10M | -42.57M | -38.53M | -1.4103 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
프로파운드 메디컬 Stock (PROF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-23 | 개시 | Lake Street | Buy |
| 2024-07-16 | 업그레이드 | Stifel | Hold → Buy |
| 2023-11-28 | 개시 | Stifel | Hold |
| 2023-08-04 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-03-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-15 | 개시 | Jefferies | Buy |
모두보기
프로파운드 메디컬 주식(PROF)의 최신 뉴스
Profound Medical Q1 2026 Earnings: EPS Beats Estimates, Stock DeclinesEarnings Beat Alert - Newser
PROF Q1 2026 Earnings: EPS Surprises to the Upside, Stock Declines 2%Community Pattern Alerts - Newser
Profound Medical (PROF) Hovers Near Support Amid Modest DeclineFactor Momentum - Newser
[EFFECT] Profound Medical Corp. SEC Filing - Stock Titan
Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High? - Yahoo Finance
Profound Medical Shareholders Back Board, Question Incentive Plan - The Globe and Mail
Telix partners with EDAP, Profound on prostate imaging tech - Investing.com UK
Profound Medical (NASDAQ: PROF) investors back board, auditor and long‑term incentive units - Stock Titan
Telix to Collaborate With EDAP, Profound Medical to Explore PSMA-PET Imaging in Prostate Cancer Therapies - Moomoo
Profound Medical Showcases TULSA-PRO Integration with PSMA PET Imaging for Prostate Cancer at AUA2026 - Minichart
Profound Medical Q1 earnings call highlights - MSN
How Profound Medical Corp. (PROF) Affects Rotational Strategy Timing - Stock Traders Daily
Profound Medical Highlights TULSA Advances at AUA 2026 - TipRanks
Profound Medical (NASDAQ: PROF) to highlight TULSA and PSMA PET integration at AUA2026 - Stock Titan
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026 - The Manila Times
Imaging combo to sharpen prostate cancer treatment planning - Stock Titan
Nearly 70% of Profound Medical shares vote to support full board slate - Stock Titan
Profound Medical Annual General and Special Meeting of Shareholders Voting Results - TMX Newsfile
TradingKey - TradingKey
Profound Medical (NASDAQ: PROF) registers 921,428 resale shares - Stock Titan
Profound Medical (PROF) price target decreased by 26.77% to 8.49 - MSN
Profound outlines ~$25M 2026 revenue, anticipates FDA clearance for Siemens Free integration by year-end - MSN
Profound Medical Q1 Earnings Call Highlights - TradingView
Profound Medical revenue up 104% in Q1 2026 - Medical Buyer
Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz - The National Law Review
Earnings call transcript: Profound Medical beats Q1 2026 forecasts By Investing.com - Investing.com Australia
Earnings call transcript: Profound Medical beats Q1 2026 forecasts - Investing.com
Profound Medical Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Profound Medical : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Profound Medical Reports Strong First Quarter 2026 Financial Results - Investing News Network
Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Profound Medical Down 8.5% After Hours as Its Q1 Loss Narrows, Revenue More Than Doubles, Beats Estimates - marketscreener.com
Profound Medical Issues FY26 Revenue Guidance and Announces Humana Is Now Covering the TULSA Procedure - marketscreener.com
Profound Medical Says Q1 Results Marked By 104% Revenue Growth and "Improved" Operating Performance - marketscreener.com
Profound Medical Q1 Basic and Diluted Net Loss Per Common Share US$0.19, Vs $0.36 a Year Ago - marketscreener.com
Humana starts covering Profound's TULSA procedure as revenue jumps 104% - Stock Titan
Profound Medical (NASDAQ: PROF) doubles Q1 revenue as losses narrow - Stock Titan
Profound Medical (NASDAQ: PROF) posts 104% Q1 2026 revenue growth - Stock Titan
When Will Profound Medical Corp. (TSE:PRN) Turn A Profit? - simplywall.st
Profound Medical : Investor Presentation (Profound Investor Presentation May 2026 ver1) - marketscreener.com
Profound Medical Corp (PROF) Q1 2026 Earnings Report Preview: Wh - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Co - The National Law Review
Profound Medical Corp. (TSE:PRN) Is Expected To Breakeven In The Near Future - Yahoo Finance
프로파운드 메디컬 (PROF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
1.94%
자본화:
|
볼륨(24시간):